"The first patient dosed with UGN-501 marks an important step in advancing this investigational therapy from nonclinical research into clinical evaluation," said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. "We can now begin to understand its safety and tolerability in patients with NMIBC and generate insights to guide its continued development. This progress brings us closer to our goal of expanding treatment options for patients with bladder cancer." The Phase 1, open-label, dose-escalation tri ...